A national multi-center open-label randomized controlled trial that investigates whether the use of the automated insulin delivery system CamAPS FX initiated during pregnancy planning or in early pregnancy improves maternal time in glycemic targets and fetal growth in women with type 1 diabetes compared to usual insulin treatment modality combined with Continuous Glucose Monitoring.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time in range
Timeframe: From first day of last menstrual cycle (planning pregnancy) or randomization (early pregnancy) until delivery.
Neonatal outcome: Birthweight
Timeframe: At delivery
Lene Ringholm Chief physician, PhD, Associate Professor